SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-126686
Filing Date
2021-04-22
Accepted
2021-04-22 16:06:13
Documents
7
Period of Report
2021-06-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A d136814ddef14a.htm DEF 14A 602973
2 GRAPHIC g136814g02a10.jpg GRAPHIC 27693
3 GRAPHIC g136814g10p85.jpg GRAPHIC 44273
4 GRAPHIC g136814g22o10.jpg GRAPHIC 47862
5 GRAPHIC g136814g22z55.jpg GRAPHIC 51706
6 GRAPHIC g136814g46s55.jpg GRAPHIC 180119
7 GRAPHIC g136814g47m66.jpg GRAPHIC 164515
  Complete submission text file 0001193125-21-126686.txt   1304893
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36352 | Film No.: 21844828
SIC: 2834 Pharmaceutical Preparations